Document is current
Any future updates will be listed below
-
Authors
Beckmann, Malte
Schlüter, Julian
Erdmann, Michael
Kramer, Rafaela
Cunningham, Sarah
Hackstein, Holger
Zimmermann, Robert
Heinzerling, Lucie
-
Funding
Funding for this research was provided by:
German Federal Ministry of Education and Research (01ZX1905A)
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 14 April 2024
Accepted: 27 September 2024
First Online: 2 November 2024
Declarations
:
: MB: no conflicts of interest to disclose JS: no conflicts of interest to disclose ME: honoraria and travel support from Bristol Myers Squibb, Immunocore, Novartis, Pierre Fabre and Sanofi, outside the submitted work RK: no conflicts of interest to disclose SC: no conflicts of interest to disclose HH: no conflicts of interest to disclose RZ: Lecture fees from CSL, Stago and Siemens, outside the submitted work LH: consultancy/ad boards BiomeDx, BMS, Immunocore, MSD, Merck, Roche, Amgen, Curevac, Novartis, Sanofi, SUN, Pierre Fabre, Takeda.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of University of Erlangen (approval #82_19B, 20.03.2019; Amendment: 26.11.2019).
: Written informed consent was obtained from all subjects involved in the study.
: Written informed consent has been obtained from the patients to publish this paper.
